Circassia is developing a broad portfolio of treatments for asthma, chronic obstructive pulmonary disease (COPD) and allergy, with several in late-stage development. The products are based on our range of proprietary technologies, which provide a number of important potential benefits.

Allergy immunotherapies

Our allergy treatments are the first in the synthetic peptide immuno-regulatory epitope class of therapies (SPIREs).

Technology: ToleroMune® allergy immunotherapies

Asthma therapies

Our particle-engineered treatments target direct substitution of several market-leading asthma products.

Technology: Particle-engineered respiratory therapies

COPD treatments

Our optimized COPD therapies leverage the company’s proprietary particle-engineering technologies. This approach offers the potential to develop novel formulations and fixed-dose combination therapies delivered in a single device.

Technology: Particle-engineered respiratory therapies